Delivery Order SPE2DB22D2007-SPE2DB25FJ4EL
- Not listed
- The Defense Logistics Agency awarded a delivery order valued at $4,361.80 to AmerisourceBergen Drug Corp on August 11, 2025, for the supply of Ozempic (semaglutide) 0.25–0.5 mg/dose pens in 3 mL formulations. This competitive award uses firm fixed pricing with no set-aside designation and is scheduled for completion by August 12, 2025. The order will be fulfilled from AmerisourceBergen's Corporate Office location in Conshohocken, Pennsylvania. This delivery order is issued under...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3 mL formulations, valued at $30,494.73. This is a firm fixed-price delivery order with an ultimate completion date of August 20, 2025, and represents a non-set-aside competitive award. The product will be delivered to the company's facility in Conshohocken, Pennsylvania. This delivery order is issued under AmerisourceBergen...
- The Defense Logistics Agency awarded AmerisourceBergen Drug Corp a delivery order valued at $8,699.67 on August 5, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3ml) with a firm fixed price arrangement. The contract, which is non-set-aside and competitively awarded, specifies a place of performance in Conshohocken, Pennsylvania, with an ultimate completion date of August 6, 2025. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite Delivery...
- AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, was awarded a delivery order by the Defense Logistics Agency valued at $6,018.43 for the supply of Ozempic (semaglutide) 0.25–0.5 mg/dose pens in 3 mL vials. The contract was competitively awarded without a set-aside designation and carries a firm fixed price structure, with an ultimate completion date of August 12, 2025. The pharmaceutical product will be distributed from the vendor's...
- The Defense Logistics Agency awarded a $35,602.74 delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3 mL format. This is a firm fixed-price, competitively awarded contract with no set-aside designation, with a performance location in Conshohocken, Pennsylvania and an ultimate completion date of August 14, 2025. The delivery order was issued on August 13, 2025, as a child contract under AmerisourceBergen's larger pharmaceutical supply...
- The Defense Logistics Agency awarded a delivery order valued at $18,198.96 to AmerisourceBergen Drug Corp for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3mL vials. The contract was competitively awarded with firm fixed pricing and is scheduled for completion by August 13, 2025. AmerisourceBergen will fulfill this order from its corporate office location in Conshohocken, Pennsylvania. This delivery order represents a child contract under AmerisourceBergen's larger Indefinite...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ozempic 0.25-0.5 mg/dose pens (3 ml) with a ceiling value of $5,654.96. This is a firm fixed-price delivery order with no set-aside designation, indicating it was competitively awarded. The contract will be performed at AmerisourceBergen's corporate office in Conshohocken, Pennsylvania, with an ultimate completion date of August 20, 2025. This delivery order is issued...
- The Defense Logistics Agency awarded a delivery order valued at $5,826.53 to AmerisourceBergen Drug Corp for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3 mL formulations. The contract is firm fixed price with no set-aside designation and was awarded on July 28, 2025, with an ultimate completion date of July 29, 2025. Performance will be executed at the awardee's facility in Conshohocken, Pennsylvania. This delivery order is a child contract under AmerisourceBergen's broader...
- The Defense Logistics Agency awarded a delivery order to AmerisourceBergen Drug Corp on August 19, 2025, for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3 ml quantities, with a ceiling value of $8,934.28. This is a firm fixed-price delivery order executed under a competitive process with no set-aside designation. The contract is set to be completed by August 20, 2025, and represents fulfillment under AmerisourceBergen's broader pharmaceutical supply agreements with the Defense...
- The Defense Logistics Agency awarded a $15,411.40 firm fixed-price delivery order to AmerisourceBergen Drug Corp for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pen 3ml formulations. The contract was competitively awarded without a set-aside designation and is scheduled for completion by July 24, 2025. AmerisourceBergen's corporate office in Conshohocken, Pennsylvania serves as the place of performance. This delivery order is issued under the company's broader Indefinite Delivery...
- SPE2DB22D2007Indefinite Delivery Contract
- SPE2DB22D2007-SPE2DB25FJ4ELDelivery Order
The Defense Logistics Agency awarded a $17,428.58 delivery order to AmerisourceBergen Drug Corp on August 20, 2025, for the supply of Ozempic (semaglutide) 0.25-0.5 mg/dose pens in 3mL formulation. This competitively awarded, firm fixed-price contract will be performed in Conshohocken, Pennsylvania, with an ultimate completion date of August 21, 2025. The delivery order is classified as a child contract under AmerisourceBergen's larger Indefinite Delivery Contract with DLA Troop Support Medical (SPE2DX), a $999,999,999 global pharmaceutical support vehicle running through December 2026 that enables the company to supply a comprehensive range of pharmaceuticals and medical supplies to support military healthcare programs worldwide. AmerisourceBergen Drug Corp, a major pharmaceutical distributor headquartered in Conshohocken, Pennsylvania, serves as a critical vendor for federal medical procurement needs across the military and veteran healthcare systems. As a primary pharmaceutical supplier to the Defense Health Agency and other government healthcare entities, the company maintains an extensive portfolio of brand-name and generic medications, vaccines, and specialized medical supplies across multiple therapeutic domains. This award reflects the company's capability to meet federal procurement requirements through open competition and its ongoing role in supporting the DLA's medical supply chain operations.
Mod # | Description | ReasonForModification | Federal Obligation | Date |
|---|---|---|---|---|
| Not listed | Not listed | $17.4k | 8/20/25 |